World ADC is pleased to publish the winners of the 7th Annual World ADC Awards, held at World ADC Digital in September.
The World ADC Awards reward the innovation, leadership, and devotion shown by the best companies, teams, and individuals in the industry. Across ten categories the Awards exist to recognize the extraordinary endeavors, teamwork and commercial acumen that has propelled the field to the forefront of cancer research today.
The Awardees were shortlisted by over 1000 nominations and then scientific proposals from each were evaluated by our Judging panel.
Elayda Hearne, Brand Director, World ADC stated: “Every year the judges are impressed with the level of innovation and scientific breakthroughs that these companies are driving. This year is no exception and we are delighted to see the calibre and quantity of entries – showing the growing momentum and advances being made within the industry”
Jagath Reddy Junutula, Sr Vice President, R&D at ModMab Therapeutics stated & World ADC Judge: “The World ADC Summit is my favorite scientific conference as it unifies all ADC players on to a single platform. In addition, World ADC Awards brings to light the excellence within the ADC field. The World ADC Awards recognizes the innovation, leadership, and devotion on a global platform. I am truly honored to be part of the judging for World ADC Awards and I am delighted to see the growth in the ADC field and the continuing momentum and progress in the ADC field”
The shortlist for Best ADC platform technology is as follows:
Ajinomoto
IntoCell
LegoChemBio
Mersana
Sutro
Synaffix
The 2020 winners are:
Best ADC Platform Technology
Winner – Synaffix
Runner Up – LegoChem Bio
Most Promising Clinical Candidate
Winner – DS-1062, Daiichi Sankyo
Runner Up – Loncastuximab Tesirine, ADC Therapeutics
Best Contract Manufacturing (CMO) Provider
Winner – Piramal
Runner Up – BSP Pharmaceuticals
Best Contract Research (CRO) Provider
Winner – Abzena
Runner Up – NJ Biopharmaceuticals
Best New Drug Developer
Winner – Sutro Biopharma
Runner Up – Mersana Therapeutics
Best Pre-Clinical Publication 2019
Czechowicz A, Palchaudhuri R, Scheck A, Hu Y, Hoggatt J, Saez B, Pang WW, Mansour MK, Tate TA, Chan YY, Walck E, Wernig G, Shizuru JA, Winau F, Scadden DT, Rossi DJ.Nat Commun. 2019 Feb 6;10(1):617. doi: 10.1038/s41467-018-08201-x.
Winner – AJICAP: Affinity Peptide Mediated Regiodivergent Functionalization of Native Antibodies.
Yamada K, Shikida N, Shimbo K, Ito Y, Khedri Z, Matsuda Y, Mendelsohn BA.Angew Chem Int Ed Engl. 2019 Apr 16;58(17):5592-5597. doi: 10.1002/anie.201814215. Epub 2019 Mar 29.
Best Clinical Publication 2019
Winner – Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators.N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017.
Individual Input to the Field 2019/2020
Winner – Aldo Braca, President & Founder, BSP Pharmaceuticals
“Very happy and honored to have received this recognition. The BSP Pharmaceuticals team is very active in trying to anticipate customer needs in development, clinical and commercial supplies. We decided to play an important role as CDMO in the ADC space ten years ago, and we have always been very consistent with this mission, trying to make available to the most qualified scientific community the means to be able to materialize its ideas as quickly as possible.
We are continuing to invest to open up new capacities, both for Drug Substances and Drug Products. We are convinced that this category of treatments is opening new horizons in the fight against cancer and, for many patients, will represent the strongest life expectancy. BSP is working on most of the new products currently in pre-clinical and clinical and also those that are in the market. We are doing it without too much noise but with a lot of passion. If such an important Community, brought together by Hanson Wade, notices us and appreciates our work, then this shows us that we are going on the right path, it repays us for the work and pushes us to do more and more ”.
Long Standing Contribution
Winner – Rakesh Dixit, President & CEO, BioNavigen
Statement from Rakesh: “World ADC, organized by Hanson Wade, is the biotech industry’s most comprehensive antibody-drug conjugate conference that enables scientists from all over the world to share the excellence in discovery and development of ADCs. Along with anticancer immunotherapies, ADCs are rapidly becoming one of the fiercest weapons against deadly cancers, and I am thrilled to have a long-standing contribution to the world of ADCs. It is a great honor and privilege to receive the prestigious “Long-Standing Contributions to the ADC Field” award from the World ADC 2020. I do not have enough words to express how grateful I am to Hanson Wade, all my peers and colleagues who nominated me and selected me to receive one of the best honors of my career. Thank you”.
For more information about the World ADC Awards, visit www.worldadc-awards.com.
About World ADC & What’s Next
Focused on ADCs and crafted with the field’s thought-leaders, World ADC is the industry’s definitive forum for learning and networking.
Your next opportunity to learn the latest ADC intelligence and foster connections with thought leaders to maximize the therapeutic index of your ADC candidate will be at World ADC Europe.
Join the ADC community for this exclusively digital meeting from March 8th-11th, 2021.